SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report – October 29, 2003
(Date of earliest event reported)
ALKERMES, INC.
| Pennsylvania | 001-14131 | 23-2472830 | ||
| (State of incorporation) | (Commission file number) | (IRS employer identification number) |
88 Sidney Street, Cambridge, Massachusetts 02139
(Address of principal executive offices, zip code)
Area Code (617) 494-0171
(Telephone number)
| Item 5. Other Information. | ||||||||
| Item 7. Financial Statements and Exhibits. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EX-99.1 PRESS RELEASE ISSUED BY ALKERMES, INC. | ||||||||
Item 5. Other Information.
On October 29, 2003, Alkermes, Inc. announced the U.S. Food and Drug Administration (FDA) approved RISPERDAL® CONSTA™ [(risperidone) long-acting injection] for the treatment of schizophrenia. A copy of the press release issued by Alkermes on October 29, 2003, is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 7. Financial Statements and Exhibits.
| (c) | Exhibits |
| 99.1 | Press Release issued by Alkermes, Inc., dated October 29, 2003. |
SIGNATURES
Pursuant to requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated: October 30, 2003 | Alkermes, Inc. | |||
| By: | /s/ Kathryn Biberstein | |||
| Kathryn Biberstein Vice President and General Counsel |
||||
ALKERMES, INC.
CURRENT REPORT ON FROM 8-K
EXHIBIT INDEX
| Exhibit No. | Exhibit | |||||
| 99.1 | Press Release issued by Alkermes, Inc., dated October 29, 2003. |